Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,890

Engineering Living Organisms Could Be the World’s Biggest Industry

Wouldn’t it be better to have a creature, something furry and warm that had the ability to produce perfect breast milk? A non-sentient, biological organism that has been engineered to produce milk nutritionally equivalent to mother’s milk? A milk Tribble? That type of technology would be awesome for babies.

Karl Schmieder: Is there a biological technology that you wished you had?

Andrew Hessel: I want the enzymatic DNA synthesizer that will be at least a thousand times better than what we have today. Next-generation sequencing technology massively accelerated our ability to read DNA. An enzymatic DNA synthesizer could be the equivalent accelerator for engineered biology. If you can synthesize DNA faster, then you can conduct more experiments and learn faster. That’s what I’d like to see. More people programming life.

Biologists create new genetic systems to neutralize gene drives

In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance. Based on CRISPR technology, such gene drives are poised to move from the laboratory into the wild where they are being engineered to suppress devastating diseases such as mosquito-borne malaria, dengue, Zika, chikungunya, yellow fever and West Nile. Gene drives carry the power to immunize mosquitoes against malarial parasites, or act as genetic insecticides that reduce mosquito populations.

Although the newest gene drives have been proven to spread efficiently as designed in laboratory settings, concerns have been raised regarding the safety of releasing such systems into wild populations. Questions have emerged about the predictability and controllability of gene drives and whether, once let loose, they can be recalled in the field if they spread beyond their intended application region.

Now, scientists at the University of California San Diego and their colleagues have developed two new active genetic systems that address such risks by halting or eliminating gene drives in the wild. On Sept.18, 2020 in the journal Molecular Cell, research led by Xiang-Ru Xu, Emily Bulger and Valentino Gantz in the Division of Biological Sciences offers two new solutions based on elements developed in the common fruit fly.

World’s First Push Button Blood Collection: No More Needles?

Ira Pastor, ideaXme life sciences ambassador, interviews Rick Bente, MSc, MBA, BS, CEO of Seventh Sense Biosystems.

Ira Pastor Comments:

Getting blood drawn is not a fun activity for many. It can be scary for some (especially if you have children); it can be painful for others (especially where frequent blood draws are required).

Studies show that a remarkable 20% of the population has some degree of fear of needles or injections, and 10% within that number suffer from what is known as Trypanophobia (a psychological term for people with an extreme fear of medical procedures involving injections or hypodermic needles), who on top of their anxiety, completely avoid necessary tests and treatment.

In addition to this, it is estimated that needles injure healthcare workers more than 2 million times a year in accidents, with potentially dangerous and deadly outcomes.

Drawing blood is likely the most common invasive medical procedure, with an estimated half a billion a year conducted in U.S. hospitals alone, and two to three times this number across all hospitals worldwide annually.

Continue reading “World’s First Push Button Blood Collection: No More Needles?” | >

Planet Earth Report –“The Age of Pandemics to MEGA Thruster Taps into Fabric of the Universe”

“Planet Earth Report” provides descriptive links to headline news by leading science journalists about the extraordinary discoveries, technology, people, and events changing our knowledge of Planet Earth and the future of the human species.

The Universe Might Be Too Thin, Scientists may have found a new crack in our understanding of the universe, reports The Atlantic and Quanta. The cosmos is starting to look a bit weird. For a few years now, cosmologists have been troubled by a discrepancy in how fast the universe is expanding. They know how fast it should be going, based on ancient light from the early universe, but apparently the modern universe has picked up too much speed—a clue that scientists might have overlooked one of the universe’s fundamental ingredients, or some aspect of how those ingredients stir together.

Common drugs linked to increased risk of Alzheimer’s

A new study suggests anticholinergic medications may increase the risk of accelerated cognitive decline, especially in older adults at high risk of developing Alzheimer’s disease.

Anticholinergic drugs block the action of acetylcholine, a chemical messenger that controls a range of automatic bodily functions and plays a vital role in memory and attention.

Doctors prescribe these drugs for a variety of conditions, including urinary incontinence, overactive bladder, chronic obstructive pulmonary disorder (COPD), seasonal allergies, and depression.

A pandemic is no time to cut the European Research Council’s funding

About 25% of all patents filed by projects supported by Horizon 2020 have come from ERC projects, even though commercialization of research is not the agency’s main aim. Bourguignon and his colleagues rightly argue that many advances in fundamental research ultimately contribute to innovation and benefit society. But that is a hard message to get across at a time of constrained funding and competing priorities.

Europe’s flagship science agency will be crucial to a post-coronavirus world. Slashing its budget will be a senseless act.

An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims

A single infusion of an experimental drug markedly reduced levels of the coronavirus in newly infected patients and lowered the chances that they would need hospitalization, the drug’s maker announced on Wednesday.

The drug is a monoclonal antibody, a manufactured copy of an antibody produced by a patient who recovered from Covid-19, the illness caused by the coronavirus. Many scientists hope that monoclonal antibodies will prove to be powerful treatments for Covid-19, but they are difficult and expensive to manufacture, and progress has been slow.

A so-called monoclonal antibody lowered levels of the coronavirus and prevented hospitalizations. The research has not yet been vetted by independent experts.